The benefits and risks of alemtuzumab in multiple sclerosis

被引：0

作者：

Ontaneda, Daniel ^{[1
]}

Cohen, Jeffrey A. ^{[1
]}

机构：

[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Neurol Inst, Cleveland, OH 44106 USA

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2013年 / 9卷 / 03期

关键词：

alemtuzumab; efficacy; multiple sclerosis; risk; THERAPEUTIC LYMPHOCYTE DEPLETION; DISEASE;

D O I：

10.1586/ECI.13.1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：189 / 191

页数：3

共 19 条

[11] Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model [J].

Hu, Yanping ;

Turner, Michael J. ;

Shields, Jacqueline ;

Gale, Matthew S. ;

Hutto, Elizabeth ;

Roberts, Bruce L. ;

Siders, William M. ;

Kaplan, Johanne M. .

IMMUNOLOGY, 2009, 128 (02) :260-270

[12] Campath-1H treatment of multiple sclerosis [J].

Jones, Joanne L. ;

Coles, Alasdair J. .

NEURODEGENERATIVE DISEASES, 2008, 5 (01) :27-31

[13] Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity [J].

Jones, Joanne L. ;

Anderson, Jane M. ;

Phuah, Chia-Ling ;

Fox, Edward J. ;

Selmaj, Krzysztof ;

Margolin, David ;

Lake, Stephen L. ;

Palmer, Jeffrey ;

Thompson, Sara J. ;

Wilkins, Alastair ;

Webber, Daniel J. ;

Compston, D. Alastair ;

Coles, Alasdair J. .

BRAIN, 2010, 133 :2232-2247

[14] IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H) [J].

Jones, Joanne L. ;

Phuah, Chia-Ling ;

Cox, Amanda L. ;

Thompson, Sara A. ;

Ban, Maria ;

Shawcross, Jacqueline ;

Walton, Amie ;

Sawcer, Stephen J. ;

Compston, Alastair ;

Coles, Alasdair J. .

JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (07) :2052-2061

[15] LONG-TERM REMISSION OF INTRACTABLE SYSTEMIC VASCULITIS WITH MONOCLONAL-ANTIBODY THERAPY [J].

LOCKWOOD, CM ;

THIRU, S ;

ISAACS, JD ;

HALE, G ;

WALDMANN, H .

LANCET, 1993, 341 (8861) :1620-1622

[16] Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis [J].

Moreau, T ;

Coles, A ;

Wing, M ;

Isaacs, J ;

Hale, G ;

Waldmann, H ;

Compston, A .

BRAIN, 1996, 119 :225-237

[17] PRELIMINARY EVIDENCE FROM MAGNETIC-RESONANCE-IMAGING FOR REDUCTION IN DISEASE-ACTIVITY AFTER LYMPHOCYTE DEPLETION IN MULTIPLE-SCLEROSIS [J].

MOREAU, T ;

THORPE, J ;

MILLER, D ;

MOSELEY, I ;

HALE, G ;

WALDMANN, H ;

CLAYTON, D ;

WING, M ;

SCOLDING, N ;

COMPSTON, A .

LANCET, 1994, 344 (8918) :298-301

[18]

Redpath S, 1998, IMMUNOLOGY, V93, P595

[19]

Stuve O, 2012, NEUROLOGY, V78

← 1 2 →